|
|
Method of treatment of skin diseases in animals Method comprises intramuscular administration of the vaccine Vakderm in a dose of 1.0 ml, subcutaneous administration of Marimix 5:0 at a dose of 3.0 ml, carrying out an external processing of a lesion area with antiparasitic agent Entomozan-C, 1 ampule per 0.5 l of water. Also, the vitamin complex based on its component vitamins A and E, an antihistamine drug and prednisone 30 mg/day are administered orally. |
|
|
Invention relates to novel chromene derivatives of formula or its salts, where: each of R1 and R3, independently, stands for hydrogen, C1-4alkyl, hydroxyl, C1-4alkoxyl, C1-4alkoxyC1-4alkyl, halogenC1-4alkyl, hydroxyC1-4alkyl, halogen or Cy2; R2 stands for hydrogen; Cy1 stands for monocyclic 5- or 6-membered heterocycle, saturated or partly unsaturated, which can be bound with remaining part of molecule by any available N atom, where Cy1 can contain 1 or 2 heteroatoms, selected from N and O, and where Cy1,optionally, has one or more substituents R4; each Cy2, independently, stands for phenyl or aromatic 5- or 6-membered cycle, which can be bound with remaining part of molecule by any available atom C or N, where Cy2 can contain in total 1 or 2 heteroatoms, selected from N and O, and where Cy2 optionally has one or more substituents R4; each R4, independently, stands for C1-4alkyl, hydroxyl, C1-4alkoxyl, halogenC1-4alkyl, hydroxyC1-4alkyl or halogen; n equals from 0 to 2; m equals 0 or 1. |
|
Method for obtaining nanocapsules of quercetin or dihydroquercetin in gellan gum Quercetin or dihydroquercetin is added to suspension of gellan gum in hexane in presence of glycerol ester with one-two molecules of food fatty acids and one-two molecules of citric acid, after that butylchloride is added by pouring, obtained suspension of nanocapules is filtered and dried, with ratio core/envelope in nanocapsules constituting 1:3. |
|
Isoindolinone-based phosphatidylinositol-3-kinase inhibitors Invention refers to pharmaceutically acceptable compositions containing the above compounds, and to methods for using the compositions for treating various diseases, conditions or disorders. |
|
Method for producing dosage form of fluorescein disodium salt preparation Invention refers to a method for producing a dosage form of fluorescein disodium salt preparation (2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid disodium salt) used for angiography in neurosurgery and ophthalmology in the form of 5-10% injection. The method consists in the fact that fluorescein disodium salt is produced by neutralising fluorescein in sodium hydroxide with potentiometric and conductometric monitoring of its efficiency. Disodium salt purity is achieved by cleaning both an intermediate product - fluorescein, and fluorescein sodium salt, using a predetermined combination of conventional cleaning procedures at all the process stages. |
|
Novel cyclopentane derivatives Claimed invention relates to compounds of formula where A1 and R1, R2, R3, R4 and R5 are determined in invention formula, which are preferable inhibitors of cathepsin cycteinprotease, in particular cathepsin S or L cycteinprotease, which makes them useful as medications, especially for treatment of diabetes, atherosclerosis, aneurism of abdominal aorta, peripheral arterial disease or diabetic nephropathy. |
|
Therapeutic nutrient composition Therapeutic nutrient composition containing a mix of dihydroquercetin, sodium alginate and ascorbic acid taken in certain mixture ratio. |
|
Method of treating patients with intestinal disbacteriosis Hepatotropic preparation Hepaguard Active is administered in a dose of 1 capsule 3 times a day at mealtimes for 28-30 days. |
|
Biologically active composition for intensive moisturising and lifting effect of skin Biologically active composition for skin care, comprising hyaluronic acid, D-panthenol, royal bee jelly, ubiquinone (coenzyme Q10), vitamin E, lemon extract and/or green tea extract, and a base at a particular ratio of components. |
|
Invention refers to a composition for preventing or treating atherosclerotic plaques in arteries. The above composition contains a combination of 50 wt/wt % of procyanidine-containing rich extracts and 50 wt/wt % of centella asiatica and/or its extracts. The invention also refers to a food stuff, a food additive, a nutriceutical, a beverage, a medicinal product containing the above component, and to a method of treating or preventing manifestations of atherosclerotic plaques in arteries. |
|
Proposed composition represents a product isolated from an unpurified caffeine phytochemical fraction where the ratio of polyphenols to caffeine is 10 - 40. The phytochemical fraction is represented by the ultrafiltration retentate produced in the process of unpurified caffeine water suspension filtration. The said unpurified caffeine represents the product of the process of caffeine removal from raw coffee beans with usage of supercritical state carbon dioxide (scCO2). The composition may be presented in the form of a food product, ready pharmaceutical form, cosmetic product, food additive or biopharmaceutical. |
|
Method of treatment of parasitic diseases of agricultural and carnivorous animals 4% solution of ivermectin in polyethylene glycol 400 is given to animals orally with drinking water at a dose of 0.01-0.03 ml per kg of animal weight. If necessary, the nonspecific and immune-correcting therapy is additionally carried out to carnivorous animals. |
|
Invention relates to agricultural industry, in particular to pesticide compounds and thereof application. Pesticide composition includes compounds, which have the following structure: (formula I), where: (a) Ar1 represents substituted phenyl, where said substituted phenyl contains one or more substituents, independently selected from C1-C6halogenalkyl and C1-C6halogenalkoxy, (b) Het represents triazolyl; Ar2 represents phenyl; (d) J represents CRJ1RJ2, where RJ1 and RJ2 are hydrogens; (e) L represents simple bond; (f) K represents NRK1; (g) Q represents O; (h) R1 represents C1-C6alkoxy; (i) R2 represents C1-C6alkoxy; (j) R3 represents OH or C1-C6alkoxy; (k) R4 represents C1-C6alkyl and (l) RK1 is independently selected from H, C1-C6alkyl, C(=O)(C1-C6alkyl) and C(=O)(C1-C6alkyl)C(=O)O(C1-C6alkyl). |
|
Method of producing of nanocapsules of vitamins b in xanthane gum Method of producing of nanocapsules of vitamins A, C, D, E or Q10 consists in that the vitamins A, C, D, E or Q10 are added to the suspension of xanthane gum in butanol, when stirring at 1300 rpm then acetonitrile is added the obtained suspension is filtered and dried under certain conditions. |
|
Method includes suspending tannin in benzene and dispersing the obtained mixture into a suspension of sodium alginate in butanol in the presence of an E472c preparation while stirring at 1000 rps. Chloroform is then added. The obtained suspension is filtered out and dried at room temperature. The process of producing microcapsules is carried out at 25°C for 20 minutes. |
|
|
Claimed are strain Lactobacillus plantarum DSM 23755, strain Lactobacillus plantarum DSM 23756,strain Lactobacillus fermentum DSM 23757 and strain Lactobacillus fermentum DSM 23758, used for preparation of product, based on fermented soya, which includes isoflavone-aglycones, equol and lunasin. Mixture of said four strains can also be used for preparation of said product. To obtain it said mixture of four strains of lactic bacteria are cultivated, inoculation of obtained after cultivation water suspension of lactic bacteria into soya-based substrates with further incubation at 30-37°C, preferably 30°C, for 48-96 h, preferably 96 h, is realised. Product, obtained by claimed method is intended for treatment of hair loss. |
|
Pharmaceutical mupirocin composition for local application Invention relates to the pharmaceutical industry and represents a water-free gel-like composition of mupirocin or its pharmaceutically acceptable salt for local application for the treatment of bacterial skin infections, containing a lipophilic base, selected from the group, consisting of vaseline, medium-chain triglycerides, isopropylmyristate and their mixtures, a bioadhesive, selected from the group, consisting of polyvinylpyrrolidone and polymethacrylates, and a solvent, selected from the group, consisting of ethanol, propanol and isopropanol. |
|
Method for increasing degree of ecdysteroid and flavonoid extraction from herbal objects Method for ecdysteriod and flavonoid extraction from herbal material comprises extraction of a mix comprising shelf fungus and an overground part of Silene viridiflora or a mix comprising redhaw hawthorn fruits and an overground part of Lychnis chalcedonica, taken at a certain ratio, by a water-alcohol solution, prepared by adding magnetic water to ethanol, wherein the water was pretreated with magnetic field of certain intensity. |
|
|
Treating polycystic ovarian syndrome in adolescent girls having the normal body weight, however no metabolic-endocrine comorbidity and active and sub-compensated chronic extragenital diseases, with the use of non-hormonal preparations is ensured by prescribing two non-hormonal target herbal preparations from the first day of spontaneous or gestagen-induced menstruation: indinol 600 mg twice a day and epigallat 1,000 mg twice a day continuously over a period of 6 months. |
|
|
Antioxidant composition containing retinol acetate in an amount of 1,650 International units (0.568 mg) - 3,300 International units (1.135 mg), α-tocopherol acetate 7.5-10 mg, ascorbic acid 35-50 mg, thiamine hydrochloride 0.581-1.0 mg, riboflavin 1.0-1.27 mg, pyridoxine hydrochloride 2.5-5.0 mg, folic acid 50-100 mg, lipoic acid 1-2 mg, ferric sulphate 2.5-5.0 mg, copper sulphate 75-400 mcg, methionine 50-100 mg, selenium 25-50 mcg is prescribed across contraception. The antioxidant composition is administered once a day, orally after meals over a period of 30 days. After 30-day pauses, the therapeutic course is repeated five times. |
|
|
Application of one or combination of phytocannabinoids for treatment of epilepsy Invention relates to medicine, namely to neurology, and can be used for treatment of partial epileptic seizures. For this purpose cannabidiol (CBD) is administered to patient in form of isolated compound or vegetable extract in amount, providing day dose of at least 400 mg. Vegetable extract contains less than 5 wt % of tetrahydrocannabinole (THC) as percentage of any cannabinoids, present in mixture composition. Application of CBD in combination with tetrahydrocannabivarin (THCV), where THCV is present in amount, providing day dose of at least 1.5 mg, is also claimed. |
|
Method of obtaining nanocapsules of vitamins in carrageenan Invention relates to a method of obtaining nanocapsules of vitamins A, C, D, E or Q10. The method of obtaining the nanocapsules of vitamins A, C, D, E or Q10 consists in the fact that a certain quantity of vitamin A, C, D, E or Q10 is added into a suspension of carrageenan in butanol, containing carrageenan in the presence of E472c, with mixing, after which hexane is added, with the further filtration of the obtained suspension and drying. The process of obtaining the nanocapsules is realised under specified conditions. |
|
Pharmaceutical composition for treating liver disease Invention relates to pharmaceutical industry, namely to composition for stimulating regeneration of damaged liver as a result of hepatectomy. Pharmaceutical composition for stimulating regeneration of damaged liver as a result of hepatectomy, contains: proanthocyanindin in effective quantity, with monomer units of proanthocyanidin having the following formula: in which when R1 represents OCH3, R2 represents OH and R3 represents H, when R1 represents OH, R2 represents H and R3 represents H, when R1 represents OH, R2 represents OH and R3 represents H, or when R1 represents OH, R2 represents OH and R3 represents OH, and R4 represents 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar or 3-(β)-O-sugar; and pharmaceutically acceptable carrier or salt, where pharmaceutically acceptable salt is selected from the group, consisting of inorganic salts of sodium, potassium, amine, magnesium, calcium, zinc, aluminium or zirconium, and organic salts of dicyclohexylamine, methyl-d-glycamine, arginine, lysine, histidine or glutamine. |
|
Pharmacological neuroprotective drug Invention concerns using comenic acid calcium salt for preventing and treating neurodegenerative diseases caused by oxidative brain damage, taken once a day daily orally on an empty stomach for 3 days. When implementing the declared application, calcium comenate has shown both the antioxidant stress-protective action, and also the pronounced neutrophic action in a combination with the neuritic growth recovery to a reference values; calcium comenate has no toxicity. |
|
Method of producing antioxidant microcapsules having sodium alginate shell Invention relates to a method of producing antioxidant microcapsules having a sodium alginate shell. Said antioxidant is quercetin, which is dissolved in methyl carbinol and the obtained mixture is dispersed into a solution of sodium alginate in acetone in the presence of an E472c preparation while stirring. Carbinol and water are then added and the obtained suspension of microcapsules is filtered out and dried. |
|
Agent possessing lymphokinetic activity Invention refers to pharmaceutical industry, particularly to an agent possessing lymphokinetic activity. The agent possessing lymphokinetic activity contains dihydroquercetin and arabinogalactan in ratio (weight parts) 1:5. |
|
|
Method for dihydroquercetin stimulation of resected liver regeneration 70% hepatic resection is performed in a laboratory animal on the second experimental day. The liver regeneration is stimulated by the intragastric administration of dihydroquercetin in a daily dose of 5.5 mg/kg every 46 hours during the first 7 experimental days. |
|
Method of production of nanocapsules of vitamins Method of production of nanocapsules of vitamin in sodium alginate is characterized in that the shell is used as sodium alginate, and the core - as the vitamin, in a weight ratio of core:shell as 1:3. According to the method of preparing the nanocapsules the vitamin is added to a suspension of sodium alginate in benzene in the presence of the preparation E472s while stirring at 1300 rev/sec. Then hexane is added, the resulting suspension is filtered and dried at room temperature. |
|
Method for producing vitamin nanocapsules in konjac gum Cores of nanocapsules are vitamins, konjac gum precipitated from an isopropanole suspension by 1,2-dichlorethane added as a non-solvent and dried at room temperature. |
|
|
Method for producing vitamin nanocapsules Invention represents a method for drug encapsulation by non-solvent addition, wherein according to the invention cores of nanocapsules are vitamins, whereas a shell is sodium carboxymethyl cellulose precipitated from isopropyl alcohol suspension by adding chloroform as a non-solvent and dried at room temperature. |
|
|
Method for combination treatment of acute alcoholic hepatitis with organic selenitium and vitamin e Integrated therapy additionally involves administering thin-walled Capsicum annuum powder of the type paprika in a dose of 30 g with the specified selenium contents of 1 mg/kg and a capsule of alpha-tocopherol acetate in a dose of 100 mg manufactured by Lyumi, LLC (Ekaterinburg) orally during meals 3 times a day. The length of the treatment is 20 days. |
|
Method of obtaining microcapsules of antioxidants in pectin Invention relates to field of encapsulation, in particular to method of obtaining microcapsules of vitamins A, C, E or Q10 in coating from highly etherified or low etherified apple or citrus pectin. In accordance with method by invention preparation E472c is added to suspension of highly etherified or low etherified apple or citrus pectin in ethanol and mixed. After that, suspension of vitamin in dimethylsulphoxide is added to suspension of pectin in ethanol, with further addition of benzene and distilled water. Obtained suspension of microcapsules is filtered and dried. Process of obtaining microcapsules is realised at 25°C for 15 min. |
|
|
2h-chromen derivatives as analgesic means Application of a compound of the general formula 1 or its spatial isomers as analgesic means is claimed. |
|
Method of treating tuberculosis with multiple drug resistance Invention refers to a method of treating tuberculosis with multiple drug resistance characterised by prescribing a combination of six anti-tuberculosis preparations in the intensive phase of chemotherapy and five preparations - in the phase of the 20-month therapy continuation, wherein the intensive phase duration makes at least 8 months until obtaining four negative culture results every month in tuberculosis with multiple drug resistance and until obtaining two negative culture results in all other cases of tuberculosis with multiple drug resistance, the phase of the therapy continuation makes 12 months. |
|
|
Method of treating drug sialoadenopathy vitamins A and E, novocaine blocades of parotid salivary glands, intake of potassium iodide solution, intake of galantamine, additionally administered is "Vezugen" in a dose of 2 tablets (capsules) 2 times per day for 30 days are administered. |
|
|
Tetrahydropyrane derivatives for neurological diseases Invention refers to a compound of the general formula |
|
Invention refers to pharmaceutical industry, namely to a method for producing a complex compound of dihydroquercetin with metal ions specified in zinc, copper (II) or calcium possessing antioxidant activity. A method consists in the fact that dihydroquercetin and metal salt is mixed in the dry state in a reactor in certain molar ratio; that is followed by adding water at a certain temperature or ethanol or aqueous-alcoholic solution at a room temperature at the controlled medium acidity; using metal salts containing weak acid anions provides medium pH equal to 5.0-5.6; using the metal salts containing strong acid anions requires reducing pH to 7 by adding an alkaline solution; the reaction is completed almost immediately for the first 5 minutes; the precipitation is filtered in water and/or ethanol; dried in air, then in a drying box to constant weight, and a complex compound is produced. The declared method enables reducing the production costs substantially and cheapening the technological process in achieving the target yield with the preset properties. |
|
Method for producing silymarin and nanoselenium agent having inhibitory action of tumour cell growth Method for producing an agent inhibitory the tumour cell growth, involving preparing a mixture of aqueous solution of selenious acid and PEG 400; that is followed by preparing a mixture of aqueous solution of hydrazine hydrochloride and PEG 400; the produced mixtures are combined; the solution is put to dialyse against distilled water; surplus of water is driven off in a rotary evaporator; the produced solution is added with silymarin dissolved in Solufor with dialysis against distilled water; pH is reduced to 7.2-7.4; the method is implemented in certain circumstances. |
|
Method for producing trivitamin microcapsules possessing supramolecular properties Invention refers to the chemical-pharmaceutical industry and represents a method for producing microcapsules possessing supramolecular properties by non-solvent addition differing by the fact that a microcapsule nucleus is trivitamin dissolved in dimethylsulphoxide, whereas a coating is xanthan gum deposited from a butanol solution by adding toluene as a non-solvent and water, which is followed by drying at room temperature. |
|
Pharmaceutical composition for treating acne and method for preparing it Invention refers to pharmaceutical industry, and represents a pharmaceutical composition in the form of gel, which contains clindamycin phosphate, a combination of gel-forming polymer and hydrophilic dispersion phase, pH control agent, allantoin and lauryliminodipropionate sodium tocopheryl phosphate; the ingredients of the composition are taken in certain ratio, in g per 100 g. |
|
Baseline therapy is accompanied by administering "Enterosgel" 1.5-2 hours prior to or 2 hours after a meal or medication intake in the children aged from 5 to 10 years old in an amount of 15 g 2 times a day, aged from 11 to 15 years old in an amount of 15 g 3 times a day for 7 days; "Qudesan" is administered orally with a meal before noon in age-specific doses: from 5 to 7 years old - 10-16 drops (15-24 mg), from 8 to 15 years old - 16-20 drops (24-30 mg), diluted in a small amount of boiled water or any other beverage of room temperature, once a day for 30 days; "Pantogam" is administered orally 15-20 minutes after a meal in age-specific doses: from 5 to 7 years old - 500 mg 2 times a day, from 8 to 15 years old - 500 mg 3 times a day for 30 days; the combined administration of the above preparations is repeated every 6 months. |
|
Anti-tumour effects of combinations of cannabis compounds Invention refers to medicine and describes a combination of tetrahydrocannabinol (THC) and cannabidiole (CBD) cannabinoids in ratio 1:5 for preparing a drug applicable in treating glioma, wherein the cannabinoid concentration falls within the range of 5 to 100 mg of the total cannabinoid concentration, wherein treating glioma involves reducing the cell survival rate, suppressing the cell growth and reducing the tumour volume. |
|
Method of treating chronic constipation and functional anorexia Invention relates to medicine, namely to gastroenterology, and can be used for the treatment of chronic constipation and functional anorexia. For this purpose, as medicinal nutrition used is a milk-vitamin mixture with the following composition (g per 100 g of the product): Proteins 24-26, Fats 27-29, Carbohydrates 33-34, minerals (mg per 100 g of the product), calcium 940-970, phosphorus 780-820, sodium 230-270, potassium 1370-1550, chloride 1270-1350, magnesium 100-125, iron 9.5-10.7, zinc 2.7-3.5, iodine 145-173, copper 76-87, manganese 45-52, vitamins (mcg per 100 g of the product) D3 7.6-8.2, E 6.2-6.8, C 42-46, B1 960-990, B2 1150-1250, Niacin11-15, B6 1370-1440, Folic acid 125-150, Pantothenic acid 2250-2370, B12 1.5-1.9, Biotin 25-31, Choline 40-45. |
|
|
Water soluble pharmaceutical composition l-arginine-dihydromeletin and method of obtaining thereof Water soluble composition consists of L-arginine and dihydromeletin in specified molar ratio. Method of obtaining water-soluble pharmaceutical composition consists in the following: mechanical activation of mixture L-arginine and dihydromeletin hydrate in argon atmosphere is carried out. |
|
|
Invention relates to medicine, namely to oncology, and can be used for treatment of cerebral glioma. For this purpose combination of cannabinoids-tetrahydrocannabinol (THC) and cannabidiol (CBD) and non-cannabinoid chemotherapeutic agent is claimed. THC and CBD ratio constitutes from 5:1 to 1:5. |
|
Compositions and methods of treating bladder cancer Invention refers to a pharmaceutical composition for treating bladder cancer. The above composition contains an effective amount of valrubicin and dimethyl sulphoxide, as well as polyethoxylated castor oil or one or more substances specified in trimethyl chitosan, mono-N-carboxymethyl chitosan, N-diethylmethyl chitosan, sodium caprylate, cytochalasin B, IL-1, polycarbophil, Carbopol 934P, N-sulphate-N,O-carboxymethyl chitosan, Zonula occludens toxin, 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine, and represents a dosage form for intra-bladder administration by instillation. The invention also refers to liposomal pharmaceutical compositions containing valrubicin, and methods of treating bladder cancer involving administering the above compositions. |
|
Compositions and methods of treating neurodegenerative diseases Claimed invention relates to novel compounds of general formula (A), their stereoisomers or pharmaceutically acceptable salts, possessing ability to inhibit activity of isomerase, taking part in visual cycle. Compounds can be applied for treatment of ophthalmological disease or disorder, such as age-related macular degeneration or Stargardt's macular dystrophy. In general formula (A) Z represents-C(R9)(R10)-C(R1)(R2)-; R1 and R2 each, independently on each other, are selected from hydrogen, halogen, C1-C5alkyl, or -OR6; or R1 and R2 together from oxo; R3 and R4 each, independently on each other, are selected from hydrogen; R6 is selected from a) C5-C15alkyl, optionally substituted with hydroxy, C1-C8alkoxy; or b) C5-C10carbocyclylalkyl, in which carbocycle is 4-, 5-, 6-, 7- or 8-member non-aromatic carbocycle, optionally substituted with hydroxy, halogen or R6CO2-; R9 and R10 each, independently on each other, is selected from hydrogen, halogen, C1-C5alkyl, optionally substituted with hydroxy, or -OR19; or R9 and R10 form oxo; or optionally, R9 and R1 together form direct bond to provide double bond; or optionally, R9 and R1 together form direct bond, and R10 and R2 together form direct bond to provide triple bond; R11 and R12 each, independently on each other, is selected from hydrogen, -C(=O)R23 or -C(NH)NH2, R23 is selected from C1-C8alkyl; R6, R19 and R34 are independently on each other are hydrogen or C1-C8alkyl; each R33 is independently selected from halogen, hydroxyl, C1-C5carboalkoxy, C1-C8alkyl, optionally substituted with hydroxy; and n equals 0 or 1. |
|
Preparation for treating and preventing alimentary anaemia in young pigs Invention refers to veterinary science and aims at treating and preventing alimentary anaemia in young pigs. A preparation contains an iron dextran complex, nanosized and zero-valent selenium (Se0), vitamin E, vitamin B12 and water in the following proportions, wt %: iron dextran complex 0.0001-80.0, selenium (Se0) 0.0001-5.0, vitamin E 0.0001-20.0, vitamin B12 0.0001-10.0, water for injections - the rest. |
|
Invention refers to the pharmaceutical industry and represents an ophthalmic solution containing riboflavin and vitamin E for the UV-A rays protection of the internal structures of an eyeball and for treating keratoconus by transepithelial crosslinking. |
|
Apoptosis-inducing agents for treating cancer and immune and autoimmune diseases Invention refers to specific compounds or their therapeutically acceptable salts presented in the patent claim and representing sulphonyl benzamide derivatives. Besides, the invention refers to a pharmaceutical composition and a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, stomach cancer, hepatocellular carcinoma, lymphoblastic leukemia, follicular lymphoma, T-cell or B-cell lymphoid process, melanoma, myelogenic leukaemia, myeloma, oral cancer, ovarian cancer, non-small-cell lung cancer, prostate cancer, small-cell lung cancer, spleen cancer with the above composition containing an excipient and a therapeutically effective amount of the sulphonyl benzamide derivative or its therapeutically acceptable salt. |
Another patent 2551084.